UNSPSC 51331703: Remoxipride

This classification denotes a dopamine antagonist with the molecular formula C16H23BrN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0223RD59PE, chemically known as (-)-(s)-3-bromo-n-((1-ethyl-2-pyrrolidinyl)methyl)-2,6-dimethoxybenzamide but generally known as remoxipride, which bears US NIH Compound Identifier 54477. European Medicines Agency schedules Remoxipride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10275MIG.

UNSPSC 51331703 Remoxipride is a Commodity-tier code that represents a single pharmaceutical product line. However, the recent state and local opportunities tagged to this code do not align with remoxipride procurement; instead, they document solicitations for naloxone, generic multi-source pharmaceuticals, and over-the-counter products distributed through authorized wholesalers and pharmacy benefit programs. State and local governments are using this code to procure pharmaceutical products and drug-related systems supporting community health, emergency response, and pharmacy benefit management initiatives, but the actual buying activity spans a broader pharmaceutical supply category than the code's nominal scope suggests. Issuing bodies include county health departments (Seminole County, Florida), state health and human services agencies (Texas Health and Human Services Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, with participants spanning Minnesota and Oregon). The mix reflects both direct county-level procurement and state-level cooperative purchasing vehicles that aggregate demand across multiple participating entities.

Recent activity is concentrated in the Southeast and Upper Midwest. Seminole County, Florida released an IFB for 1,900 units of naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries due July 26, 2023. Texas Health and Human Services Commission issued an RFI on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. The Minnesota Department of Administration's MMCAP released an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products to be supplied through authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson), with proposals due March 26, 2026 and contract awards effective July 1, 2026. Vendors supplying under these opportunities must comply with cGMP and Drug Supply Chain Security Act requirements, maintain insurance coverage including $5,000,000 commercial general liability, and accept fixed-fee or negotiated net pricing structures. The code shows limited recent activity volume; sourcing opportunities are sparse and episodic rather than continuous across multiple jurisdictions.